JP2016516726A5 - - Google Patents

Download PDF

Info

Publication number
JP2016516726A5
JP2016516726A5 JP2016503307A JP2016503307A JP2016516726A5 JP 2016516726 A5 JP2016516726 A5 JP 2016516726A5 JP 2016503307 A JP2016503307 A JP 2016503307A JP 2016503307 A JP2016503307 A JP 2016503307A JP 2016516726 A5 JP2016516726 A5 JP 2016516726A5
Authority
JP
Japan
Prior art keywords
seq
sequence
positions
angptl4 polypeptide
homology
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016503307A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016516726A (ja
Filing date
Publication date
Priority claimed from US13/841,240 external-priority patent/US9139629B2/en
Application filed filed Critical
Priority claimed from PCT/US2014/030009 external-priority patent/WO2014145275A1/en
Publication of JP2016516726A publication Critical patent/JP2016516726A/ja
Publication of JP2016516726A5 publication Critical patent/JP2016516726A5/ja
Pending legal-status Critical Current

Links

JP2016503307A 2013-03-15 2014-03-15 ネフローゼ症候群及び関連状態の治療方法 Pending JP2016516726A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/841,240 2013-03-15
US13/841,240 US9139629B2 (en) 2010-06-05 2013-03-15 Methods for treatment of nephrotic syndrome and related conditions
PCT/US2014/030009 WO2014145275A1 (en) 2013-03-15 2014-03-15 Methods for treatment of nephrotic syndrome and related conditions

Publications (2)

Publication Number Publication Date
JP2016516726A JP2016516726A (ja) 2016-06-09
JP2016516726A5 true JP2016516726A5 (https=) 2017-04-20

Family

ID=51537930

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016503307A Pending JP2016516726A (ja) 2013-03-15 2014-03-15 ネフローゼ症候群及び関連状態の治療方法

Country Status (8)

Country Link
EP (1) EP2970416B1 (https=)
JP (1) JP2016516726A (https=)
KR (1) KR102221041B1 (https=)
CN (1) CN105229024A (https=)
AU (1) AU2014233219B2 (https=)
CA (3) CA2906982C (https=)
NZ (1) NZ712935A (https=)
WO (1) WO2014145275A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101706296B1 (ko) 2015-12-21 2017-02-13 주식회사 브레인온 기억력, 학습력, 인지력 향상용 조성물
US20180201645A1 (en) * 2015-12-21 2018-07-19 Brainon Inc. Composition for improving memory, learning ability, and cognitive ability
EP3803412A1 (en) 2018-06-01 2021-04-14 Laboratory Corporation of America Holdings Simplified biosample processing for lc-ms/ms
CN112292125B (zh) * 2018-06-22 2023-10-31 西奈克制药有限公司 蛋白尿的治疗

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT1781698T (lt) * 2004-07-20 2016-09-26 Genentech, Inc. Į angiopoetiną panašaus baltymo 4 kompozicijos ir panaudojimo būdai
US9475850B2 (en) * 2010-06-05 2016-10-25 The Uab Research Foundation Methods for treatment of nephrotic syndrome and related conditions
EP3318269B1 (en) * 2010-06-05 2024-03-13 Chugh, Sumant S. Use of an angiopoietin-like 4 (angptl4) polypeptide in the manufacture of a medicament for the treatment of proteinuria.
US20110301103A1 (en) * 2010-06-05 2011-12-08 Chugh Sumant S Methods of Treatment

Similar Documents

Publication Publication Date Title
JP2015517488A5 (https=)
PE20220938A1 (es) Compuestos agonistas de gipr
JP2015517489A5 (https=)
JP2016538885A5 (https=)
JP2017512186A5 (https=)
JP2015518818A5 (https=)
JP2016516726A5 (https=)
MX2012007410A (es) Compuestos antivirales novedosos.
JP2012176978A5 (https=)
JP2013533273A5 (https=)
JP2012136541A5 (https=)
JP2013136622A5 (https=)
BR112015014457A2 (pt) composto ou sal farmaceuticamente aceitável do mesmo e composição farmacêutica e respectivos usos e processos para melhorar ou tratar infecção de hcv, para inibir a atividade da ns5b polimerase do vírus da hepatite c e a replicação de vírus da hepatite c
NZ610315A (en) Antiviral condensed heterocyclic compounds
MX2017004592A (es) Formulaciones farmaceuticas para la administracion oral de farmacos peptidicos o proteinicos.
BR112012033715A2 (pt) inibidores de quinase de regulação de sinal de apoptose.
JP2015511821A5 (https=)
JP2014169326A5 (https=)
JP2019513752A5 (https=)
PH12018500261B1 (en) Azole benzene derivative
FI3155017T3 (fi) Parannettuja peptidilääkkeitä insuliiniresistenssiin
CU20160013A7 (es) Polipéptidos cíclicos para el tratamiento de la insuficiencia cardíaca
JP2014529399A5 (https=)
JPWO2019156137A5 (https=)
JP2017532343A5 (https=)